Yoshihisa Matsumoto

Dr. Yoshihisa Matsumoto

Laboratory for Zero-Carbon Energy, Tokyo Institute of Technology, Institute of Innovative Research, N1-30 2-12-1 Ookayama, Meguro-ku, Tokyo 152-8550, Japan
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2004 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
YHYoshio Hosoi
Yoshio Hosoi
TWToshiaki Watanabe
Toshiaki Watanabe
KNKeiichi Nakagawa
Keiichi Nakagawa
Yoshihisa MatsumotoYoshihisa Matsumoto
Yoshihisa Matsumoto
AEAtsushi Enomoto
Atsushi Enomoto
NSNorio Suzuki
Norio Suzuki
Tumor tissues and adjacent normal tissues in 12 colorectal cancers were examined for quantitative differences in: i) activity of DNA-dependent protein kinase (DNA-PK), which functions in DNA double-strand breads repair, and ii) protein and mRNA levels of Ku70, Ku80, DNA-PKcs and transcriptional factor Sp1. DNA-PK activity and protein/mRNA levels of Ku70, Ku80, DNA-PKcs and Sp1 were significantly higher in the tumor tissues compared with the normal tissues. Significant correlations between DNA-PK activity and protein/mRNA levels of Ku70, Ku80, DNA-PKcs and Sp1 were observed. Because Ku80 and DNA-PKcs have consensus Sp1 recognition elements in their promoter region, the DNA sequence of Ku70 promoter region was analyzed. Analysis of Ku70 promoter region reveled that Ku70 gene has consensus Sp1 recognition elements in its promoter region. mRNA levels of Ku70, Ku80 and DNA-PKcs were correlated with one another, and significant correlations between Sp1 protein level and mRNA levels of Ku70 and Ku80 were observed. These results suggest that DNA-PK activity and protein- and mRNA-levels of Ku70, Ku80 and DNA-PKcs were elevated in tumor tissues in patients with colorectal cancer because of elevated Sp1 protein levels in tumor tissues.

5 September 2002 in Cancer
Verified
Journal Article
Open access
PDF file
YKYasuhiro Komuro
Yasuhiro Komuro
TWToshiaki Watanabe
Toshiaki Watanabe
YHYoshio Hosoi
Yoshio Hosoi
Yoshihisa MatsumotoYoshihisa Matsumoto
Yoshihisa Matsumoto
KNKeiichi Nakagawa
Keiichi Nakagawa
HNHirokazu Nagawa
Hirokazu Nagawa
BACKGROUND: Preoperative radiotherapy reduces the rate of local recurrence and improves the chance of survival in patients with resectable, advanced rectal carcinoma. However, because not all tumors respond similarly to radiation, sorting out suitable patients is required to irradiate tumors rationally. The authors examined the possible role of Ku protein in determining tumor radiosensitivity and disease free survival in patients with rectal carcinoma.METHODS: The authors studied 96 patients with advanced rectal carcinoma. In preradiation biopsy specimens of tumor samples, the number of cells that were stained positive for Ku protein was evaluated by immunohistochemistry. The expression pattern of Ku protein was examined for an association between tumor radiosensitivity (which was determined according to T classification downstaging, complete pathologic response, or Response Evaluation Criteria in Solid Tumors) and disease free survival.RESULTS: There was a high degree of correlation between the percentage of cells that expressed the 70‐kDa Ku protein (Ku70) and the 86‐kDa Ku protein (Ku86) in the tumor sections (correlation coefficient = 0.85; P < 0.001). The expression pattern of Ku protein was correlated not only with tumor radiosensitivity but also with disease free survival. Pathologic TMN classification, histopathologic grade, and Ku70 expression were significant prognostic variables for disease free survival in a multivariate analysis (P = 0.0031, P = 0.030, and P = 0.023, respectively).CONCLUSIONS: Ku70 and Ku86 raise the predictive possibility of tumor radiosensitivity. Ku may be a useful parameter for selecting patients with rectal carcinoma for preoperative radiotherapy. Cancer 2002;95:1199–205. © 2002 American Cancer Society.DOI 10.1002/cncr.10807

21 June 2001 in Oncogene
Verified
Journal Article
Closed access
PDF file
NMNobuko Mori
Nobuko Mori
Yoshihisa MatsumotoYoshihisa Matsumoto
Yoshihisa Matsumoto
MOMasaaki Okumoto
Masaaki Okumoto
NSNorio Suzuki
Norio Suzuki
JYJyoji Yamate
Jyoji Yamate

25 September 2001 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
YHYoshio Hosoi
Yoshio Hosoi
HMHideo Miyachi
Hideo Miyachi
Yoshihisa MatsumotoYoshihisa Matsumoto
Yoshihisa Matsumoto
AEAtsushi Enomoto
Atsushi Enomoto
KNKeiichi Nakagawa
Keiichi Nakagawa
TOTetsuya Ono
Tetsuya Ono
We have previously reported the antimetastatic effects and augmentation of immune responses, which would be a mechanism of the antimetastatic effects, of 0.1 to 0.2 Gy total body irradiation. To elucidate the cellular mechanisms of the augmentation of immune response, we investigated the effects of low‐dose irradiation on gene expression of interleukin‐1β (IL‐1β) and IL‐6 using mouse peritoneal macrophages in vitro. Absolute mRNA quantification was carried out using competitive polymerase chain reaction. Gene expression of IL‐1β and IL‐6 was increased 1 to 2 hr after 2.0 Gy irradiation and then decreased to below the basal expression level 4 hr after irradiation. Irradiation with 0.1 Gy increased IL‐6 expression 2 hr after irradiation, but it did not affect IL‐1β expression. Downregulation of IL‐1β and IL‐6 observed 4 hr after 2.0 Gy irradiation was not observed with 0.1 Gy irradiation. The protein kinase C (PKC) inhibitor H7 and the phosphatidylinositol 3‐kinase (PI3‐kinase) inhibitor wortmannin inhibited induction of IL‐1β and IL‐6 expression, which suggests that radiation‐induced IL‐1β and IL‐6 expression is achieved by PKC‐ and PI3‐kinase‐mediated signaling.

Verified
Journal Article
Open access
PDF file
Yoshihisa MatsumotoYoshihisa Matsumoto
Yoshihisa Matsumoto
DNA double-strand break (DSB) is considered the most deleterious type of DNA damage, which is generated by ionizing radiation (IR) and a subset of anticancer drugs. DNA-dependent protein kinase (DNA-PK), which is composed of a DNA-PK catalytic subunit (DNA-PKcs) and Ku80-Ku70 heterodimer, acts as the molecular sensor for DSB and plays a pivotal role in DSB repair through non-homologous end joining (NHEJ). Cells deficient for DNA-PKcs show hypersensitivity to IR and several DNA-damaging agents. Cellular sensitivity to IR and DNA-damaging agents can be augmented by the inhibition of DNA-PK. A number of small molecules that inhibit DNA-PK have been developed. Here, the development and evolution of inhibitors targeting DNA-PK for cancer therapy is reviewed. Significant parts of the inhibitors were developed based on the structural similarity of DNA-PK to phosphatidylinositol 3-kinases (PI3Ks) and PI3K-related kinases (PIKKs), including Ataxia-telangiectasia mutated (ATM). Some of DNA-PK inhibitors, e.g., NU7026 and NU7441, have been used extensively in the studies for cellular function of DNA-PK. Recently developed inhibitors, e.g., M3814 and AZD7648, are in clinical trials and on the way to be utilized in cancer therapy in combination with radiotherapy and chemotherapy.

1 January 2005 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
MSMasanori Someya
Masanori Someya
KSKoh-Ichi Sakata
Koh-Ichi Sakata
Yoshihisa MatsumotoYoshihisa Matsumoto
Yoshihisa Matsumoto
HYHiroyuki Yamamoto
Hiroyuki Yamamoto
MMManami Monobe
Manami Monobe
MHMasato Hareyama
Masato Hareyama
The DNA double-strand breaks (DSBs) repair pathway has been implicated in maintaining genomic integrity via suppression of chromosomal rearrangements. DNA-dependent protein kinase (DNA-PK) has an important role with DNA DSBs repair. In this study, 93 of untreated cancer patients and 41 of cancer-free healthy volunteers were enrolled. Peripheral blood was collected, separated and centrifuged; DNA-PK activity was measured by DNA-pull-down assay. The expressions of DNA-PKcs, Ku70 and Ku86 were examined by RT–PCR assay and western blotting. Chromosomal aberrations were examined by cytogenetic methods. DNA-PK activities of peripheral blood lymphocytes (PBL) in patients with uterine cervix or breast cancer were significantly lower than those in normal volunteers. Age and smoking had no association with DNA-PK activity, whereas DNA-PK activity and the expression of Ku70, Ku86 and DNA-PKcs in RT–PCR were interrelated. A similar tendency was seen in western blot assay but less clear than in RT–PCR. Therefore, the association between DNA-PK activity and expression of DNA-PK in protein level could not be concluded. The frequency of chromosome aberration, such as dicentric chromosomes and excess fragment increased as the DNA-PK activity decreased. In conclusion, DNA-PK activity is associated with chromosomal instability. DNA-PK activity in PBL is associated with risk of breast and uterine cervix cancer. DNA-PK activity in PBL can be used to select individuals for whom an examination should be performed because of their increased susceptibility to breast and uterine cervix cancer.